巴曲酶联合前列地尔治疗下肢动脉硬化闭塞症的效果分析

Analysis of effect of batroxobin combined with alprostadil in treatment of arteriosclerosis obliterans of lower extremities

目的 探讨巴曲酶联合前列地尔治疗下肢动脉硬化闭塞症的临床效果。方法 回顾性分析郑州大学第一附属医院2020年1月至2021年8月收治的下肢动脉硬化闭塞症患者,筛选符合纳入标准的患者156例,将单纯应用前列地尔治疗的78例患者纳为对照组,应用巴曲酶联合前列地尔治疗的78例患者纳为观察组,治疗疗程为14 d。比较两组患者治疗前后的纤维蛋白原指标、踝肱指数及临床症状的评分改变,进行疗效分析。结果 应用巴曲酶联合前列地尔治疗后,观察组患者血纤维蛋白原从治疗前的(4.17±1.41)g/L下降至(2.83±1.11)g/L,应用前列地尔治疗后,对照组患者血纤维蛋白原从治疗前的(4.01±2.47)g/L下降至(3.92±1.08)g/L,均较治疗前降低,而观察组纤维蛋白原较对照组下降明显,差异均有统计学意义(P<0.05);应用巴曲酶联合前列地尔治疗后,观察组患者踝肱指数从治疗前的(0.36±0.05)上升至(0.93±0.04),应用前列地尔治疗后,对照组患者ABI从治疗前的(0.37±0.05)上升至(0.89±0.03),均较治疗前升高,差异均具有统计学意义(P<0.05),且观察组踝肱指数增加幅度高于对照组,差异有统计学意义(P<0.05);应用巴曲酶联合前列地尔治疗后,观察组的临床总有效率(94.9%)优于对照组(92.3%)(P<0.05)。结论 巴曲酶联合前列地尔治疗下肢动脉硬化闭塞症相对于单纯应用前列地尔改善临床效果更好,减轻症状更明显,值得临床推广。

Objective To investigate the clinical effect of batroxobin combined with alprostadil in the treatment of arteriosclerosis obliterans of lower extremities.Methods The patients with arteriosclerosis obliterans of lower extremities treated in the first affiliated Hospital of Zhengzhou University from January 2020 to August 2021 were retrospectively analyzed.156 patients who met the inclusion criteria were selected.The patients treated with alprostadil alone were taken as the control group(n=78) and the patients treated with batroxobin combined with alprostadil as the observation group(n=78).The course of treatment was 14 days.The changes of fibrinogen index, ankle-brachial index and clinical symptoms of the two groups before and after treatment were compared, and the curative effect was analyzed.Results After treatment with batroxobin and alprostadil, the blood fibrinogen decreased from(4.17±1.41) g/L to(2.83±1.11) g/L in the observation group, and from(4.01±2.47) g/L to(3.92±1.08) g/L in the control group after treatment with alprostadil.The level of fibrinogen in the observation group was significantly lower than that in the control group, and the difference was statistically significant(P<0.05).After treatment with batroxobin and alprostadil, the ABI of the patients in the observation group increased from(0.36±0.05) to(0.93±0.04).After the treatment with alprostadil, the ABI of the patients in the control group increased from(0.37±0.05) to(0.89±0.03).The difference was statistically significant(P<0.05),and the increase of ankle-brachial index in the observation group was higher than that in the control group.The difference was statistically significant(P<0.05).After treatment with batroxobin combined with alprostadil, the total clinical effective rate of the observation group(94.9%) was better than that of the control group(92.3%)(P<0.05).Conclusion Batroxobin combined with alprostadil in the treatment of arteriosclerosis obliterans of lower extremities is better than alprostadil in improving clinical effect and relieving symptoms, which is worthy of clinical promotion.